百亞股份(003006.SZ):預計今年電商渠道將實現盈虧平衡,略盈利狀態
格隆匯10月23日丨百亞股份(003006.SZ)投資者關係活動記錄表顯示,隨着外圍省份不斷拓展,產品和渠道結構不斷優化,大健康系列產品佔比高於公司平均水平,推動了區域毛利率水平持續提升。當前公司的全國化拓展模式符合公司預期,外圍省份整體尚未實現盈利,主要是市場拓展前期費用投入較大。隨着公司品牌知名度持續提升,渠道基礎和消費者沉澱持續向好,外圍省份市場有望達成年度目標,盈利能力也將進一步提升,部分省份市場預計明年將能實現盈利。
單三季度,公司電商渠道略有盈利,公司在加大線上平台的營銷資源投入,4季度也會保持一定的投入力度,預計今年電商渠道將實現盈虧平衡,略盈利狀態。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.